DE60319739T2 - Escitalopramhydrobromid und ein verfahren zu dessen herstellung - Google Patents

Escitalopramhydrobromid und ein verfahren zu dessen herstellung Download PDF

Info

Publication number
DE60319739T2
DE60319739T2 DE60319739T DE60319739T DE60319739T2 DE 60319739 T2 DE60319739 T2 DE 60319739T2 DE 60319739 T DE60319739 T DE 60319739T DE 60319739 T DE60319739 T DE 60319739T DE 60319739 T2 DE60319739 T2 DE 60319739T2
Authority
DE
Germany
Prior art keywords
disorder
escitalopram
disorders
treatment
escitalopram hydrobromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319739T
Other languages
German (de)
English (en)
Other versions
DE60319739D1 (de
Inventor
Lawrence Manchester MARTEL
Robert Dancer
Hans Petersen
Peter Ellegaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60319739(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE60319739D1 publication Critical patent/DE60319739D1/de
Application granted granted Critical
Publication of DE60319739T2 publication Critical patent/DE60319739T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60319739T 2002-12-23 2003-12-18 Escitalopramhydrobromid und ein verfahren zu dessen herstellung Expired - Lifetime DE60319739T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200202005 2002-12-23
DKPA200202005 2002-12-23
PCT/DK2003/000902 WO2004056791A1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (2)

Publication Number Publication Date
DE60319739D1 DE60319739D1 (de) 2008-04-24
DE60319739T2 true DE60319739T2 (de) 2008-07-17

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319739T Expired - Lifetime DE60319739T2 (de) 2002-12-23 2003-12-18 Escitalopramhydrobromid und ein verfahren zu dessen herstellung

Country Status (32)

Country Link
US (1) US20040167209A1 (cg-RX-API-DMAC7.html)
EP (1) EP1578738B1 (cg-RX-API-DMAC7.html)
JP (2) JP4658613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050086933A (cg-RX-API-DMAC7.html)
CN (1) CN100349885C (cg-RX-API-DMAC7.html)
AR (1) AR042652A1 (cg-RX-API-DMAC7.html)
AT (1) ATE388947T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003287919B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317623A (cg-RX-API-DMAC7.html)
CA (1) CA2511142A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107451T1 (cg-RX-API-DMAC7.html)
DE (1) DE60319739T2 (cg-RX-API-DMAC7.html)
DK (1) DK1578738T3 (cg-RX-API-DMAC7.html)
EA (1) EA013116B1 (cg-RX-API-DMAC7.html)
EG (1) EG24729A (cg-RX-API-DMAC7.html)
ES (1) ES2298595T3 (cg-RX-API-DMAC7.html)
IL (1) IL169125A0 (cg-RX-API-DMAC7.html)
IS (1) IS2654B (cg-RX-API-DMAC7.html)
ME (1) MEP5808A (cg-RX-API-DMAC7.html)
MX (1) MXPA05005772A (cg-RX-API-DMAC7.html)
MY (1) MY135468A (cg-RX-API-DMAC7.html)
NO (1) NO20053595L (cg-RX-API-DMAC7.html)
NZ (1) NZ540281A (cg-RX-API-DMAC7.html)
PE (1) PE20040924A1 (cg-RX-API-DMAC7.html)
PL (1) PL378275A1 (cg-RX-API-DMAC7.html)
PT (1) PT1578738E (cg-RX-API-DMAC7.html)
RS (1) RS51092B (cg-RX-API-DMAC7.html)
TW (1) TW200501943A (cg-RX-API-DMAC7.html)
UA (1) UA80170C2 (cg-RX-API-DMAC7.html)
UY (1) UY28148A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004056791A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504109B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2042499B1 (en) * 2006-07-11 2018-06-27 Mitsubishi Tanabe Pharma Corporation Salt of a morpholine compound
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
HK1043129B (zh) * 1999-10-25 2004-10-21 H‧隆德贝克有限公司 西酞普蘭的製備方法
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
ES2223959T3 (es) * 2000-12-04 2005-03-01 Westfalia Separator Ag Procedimiento de pretratamiento de aceites en bruto y grasas en bruto para la produccion de esteres de acidos grasos.
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
NZ540281A (en) 2008-07-31
MXPA05005772A (es) 2005-08-16
ES2298595T3 (es) 2008-05-16
EP1578738B1 (en) 2008-03-12
EG24729A (en) 2010-06-21
CA2511142A1 (en) 2004-07-08
EA013116B1 (ru) 2010-02-26
IL169125A0 (en) 2009-02-11
BR0317623A (pt) 2005-11-29
US20040167209A1 (en) 2004-08-26
MEP5808A (xx) 2010-02-10
DE60319739D1 (de) 2008-04-24
JP2006514952A (ja) 2006-05-18
ZA200504109B (en) 2006-08-30
MY135468A (en) 2008-04-30
AR042652A1 (es) 2005-06-29
KR20050086933A (ko) 2005-08-30
AU2003287919A1 (en) 2004-07-14
JP2011037893A (ja) 2011-02-24
UA80170C2 (en) 2007-08-27
ATE388947T1 (de) 2008-03-15
CY1107451T1 (el) 2012-12-19
RS51092B (sr) 2010-10-31
IS2654B (is) 2010-08-15
JP4658613B2 (ja) 2011-03-23
IS7848A (is) 2005-05-17
PL378275A1 (pl) 2006-03-20
UY28148A1 (es) 2004-09-30
AU2003287919B2 (en) 2009-11-12
DK1578738T3 (da) 2008-06-30
HK1087708A1 (en) 2006-10-20
RS20050487A (sr) 2007-06-04
CN1726202A (zh) 2006-01-25
PE20040924A1 (es) 2004-12-11
EP1578738A1 (en) 2005-09-28
NO20053595L (no) 2005-09-05
PT1578738E (pt) 2008-04-11
EA200501046A1 (ru) 2005-12-29
TW200501943A (en) 2005-01-16
WO2004056791A1 (en) 2004-07-08
CN100349885C (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
DE29724281U1 (de) 4-Phenylpiperidin-Verbindungen
DE2500110A1 (de) 3-aryloxy-3-phenylpropylamine und verfahren zu ihrer herstellung
CH691536A5 (de) Verfahren zur Herstellung von reinem Citalopram
CH691535A5 (de) Verfahren zur Herstellung von reinem Citalopram.
DE2415082B2 (de) 1-(cumaran-5-yl-methyl)-piperazine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE2002840A1 (de) 2,3,5-trisubstit,-2'-Hydroxy-6,7-benzomorphane und Verfahren zu deren Herstellung
DE602005003791T2 (de) Verfahren zur herstellung von 1-(2s,3s)-2-benzhydril-n-(5-tert.-butyl-2-methoxybenzyl)chinuklidin-3-amin
EP1578738B1 (en) Escitalopram hydrobromide and a method for the preparation thereof
DE602004010410T2 (de) Polymorphe form von 3-phenylsulfonyl-8-piperazin-1-yl-chinolin
DE69406406T2 (de) Derivate von n,n,n',n'-tetrasubstituierten 1,2-ethylendiamin-verbindungen
DE2406065C2 (de) Neue Isoindolin-1-on-Derivate, deren Säureadditionssalze ihre Herstellung und die Zusammensetzungen, die sie enthalten
DE1245357B (de) Verfahren zur Herstellung von basischen AEthern von substituierten Hydroxybenzoesaeureamiden
DE602005003678T2 (de) Gemischtes olanzapinsolvat, verfahren zu dessen herstellung und verfahren zur herstellung von olanzapin-form i daraus
DE60000661T2 (de) Eine methode zur herstellung eines polymorphes von einem doxazosin-mesylat
DE69913377T2 (de) Gemischte Paroxetin-Propan-2-ol-Solvate
DE10359154A1 (de) Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
DE10164725B4 (de) Verfahren zur Herstellung von gereinigtem Citalopram
CH495950A (de) Verfahren zur Herstellung von neuen racemischen oder optisch aktiven 1-Nitrilophenoxy- oder 1-Alkinyloxyphenoxy-2-hydroxy-3-tert.-butylaminopropanen und deren Salzen
AT282595B (de) Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen
DE1922280B2 (de) l-Methyl-5-(3'-dimethylaminopropyliden)-5Hdibenzo [a,d] -cyclohepten-N-oxid und dessen Säureadditionssalze, sowie Verfahren zu deren Herstellung und diese Verbindungen enthaltende Präparate
AT282586B (de) Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen
AT282592B (de) Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen
DE10112828C1 (de) Verfahren zur Herstellung von Citalopram
DE60315267T2 (de) Gereinigte citalopram salze
DE60301264T2 (de) Amorphe citalopram salze

Legal Events

Date Code Title Description
8364 No opposition during term of opposition